Polymarket Market
Prediction market
Track current outcome prices, market depth, volume, liquidity, and recent trades for Prediction market.
Upcoming
- Probability
- Unavailable
Outcomes
Market outcomes
Live pricing
Pricing and liquidity
Current bid, ask, midpoint, spread, and market depth for this outcome.
- Best bid
- Unavailable
- Best ask
- Unavailable
- Midpoint
- Unavailable
- Spread
- Unavailable
- Last trade
- Unavailable
- Depth
- Unavailable
Price history
Waiting for price history
History unavailable
Bids
| Price | Size |
|---|
Asks
| Price | Size |
|---|
Trades
Recent trades
Latest visible trades for this market.
- FDA approves Sanofi’s Rilzabrutinib for immune thrombocytopenia?Yes 99% 1.03 shares
- FDA approves Sanofi’s Rilzabrutinib for immune thrombocytopenia?No 10% 10 shares
- FDA approves Sanofi’s Rilzabrutinib for immune thrombocytopenia?Yes 99% 200 shares
- FDA approves Sanofi’s Rilzabrutinib for immune thrombocytopenia?Yes 94.1% 178.53 shares
- FDA approves Sanofi’s Rilzabrutinib for immune thrombocytopenia?Yes 94% 1.06 shares
- FDA approves Sanofi’s Rilzabrutinib for immune thrombocytopenia?No 40% 39 shares
- FDA approves Sanofi’s Rilzabrutinib for immune thrombocytopenia?Yes 86% 2.03 shares
- FDA approves Sanofi’s Rilzabrutinib for immune thrombocytopenia?Yes 86% 2.05 shares
- FDA approves Sanofi’s Rilzabrutinib for immune thrombocytopenia?Yes 86% 1.16 shares
- FDA approves Sanofi’s Rilzabrutinib for immune thrombocytopenia?No 40% 5 shares
- FDA approves Sanofi’s Rilzabrutinib for immune thrombocytopenia?Yes 86% 3.49 shares
- FDA approves Sanofi’s Rilzabrutinib for immune thrombocytopenia?No 39% 2.56 shares